<DOC>
	<DOCNO>NCT03103399</DOCNO>
	<brief_summary>The purpose study investigate effect `` wearing-off '' phenomenon 3 different dos nebicapone ( NEB 50 mg , 100 mg 150 mg ) , compare entacapone placebo dministered concomitantly exist treatment levodopa plus dopa decarboxylase inhibitor ( DDCI : carbidopa benserazide ) .</brief_summary>
	<brief_title>Efficacy Tolerability Nebicapone Parkinson 's Disease Patients With `` Wearingoff '' Phenomenon</brief_title>
	<detailed_description>The study conduct 40 site Europe South America : Argentina ( 6 ) ; Austria ( 2 ) ; Brazil ( 5 ) ; France ( 1 ) ; Hungary ( 4 ) ; Poland ( 7 ) ; Portugal ( 2 ) ; Romania ( 7 ) ; Ukraine ( 6 ) . Multicentre study screen visit ( Visit V1 ) , single-blind placebo run-in period 1 2 week ( Period 1 , Visits V2 V3 ) , 8-week randomise , double-blind , activeand placebo-controlled , parallel-group ( 5 group ) treatment period ( Period 2 , Visits V3 V7 ) . In Hungary : 1-week tapering-off period add amendment # 1HU . The dosage nebicapone taper stepwise 6 day . This period end follow-up Visit V8 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Dopa Decarboxylase</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Aromatic Amino Acid Decarboxylase Inhibitors</mesh_term>
	<criteria>At Visit V1 ( screen ) , patient be/have : Ability comprehend willingness sign inform consent form Aged 30 80 year , inclusive Diagnosis idiopathic Parkinson 's disease accord Brain Bank Clinical Diagnosis Criteria UK Parkinson 's Disease Society [ Hughes et al , 1992 ] Disease severity less Stage 5 ( modify Hoehn &amp; Yahr staging ) `` '' time Treated levodopa plus DDCI least 1 year clear clinical improvement Treated 4 8 ( inclusive ) daily dose standard levodopa plus DDCI ( bedtime dose slowrelease formulation permit ) Stable regimen levodopa plus DDCI anti Parkinson drug least 4 week screen Signs endofdose `` wearingoff '' phenomenon ( endofdose deterioration ) average total daily `` '' time awake least 1.5 hour exclude early morning pre first dose `` '' period despite optimal anti Parkinson therapy , determine subjectively objectively ( observation investigator ) minimum 2 month screen Ability keep reliable diary motor fluctuation ( alone family/caregiver assistance ) Patient must amenorrhoeic least 1 year surgically sterile least 6 month screen . In case woman childbearing potential , patient must use doublebarrier contraceptive method . At Visit V2 ( entry Period 1 ) , patient result laboratory test acceptable investigator ( clinically relevant well patient purpose study ) . At Visit V3 ( randomisation ) , patient : At least 80 % treatment medication ( levodopa/DDCI plus investigational product ) compliance recommend dosage regimen Period 1 Selfrating diary chart fill accordance diary chart instruction ; le 3 error per day allow Average least 1.5 `` '' hour per day ( exclude early morning pre first dose `` '' period ) 3 day diary , fill 3 day precede Visit V3 , accord selfrating diary chart complete Period 1 At Visit V1 ( screen ) , patient be/have : Nonidiopathic Parkinson 's disease ( atypical parkinsonism , symptomatic parkinsonism , Parkinsonplus syndrome ) Dyskinesia disability score 3 Unified Parkinson 's Disease Rating Scale ( UPDRS ) IV.A item 33 Diagnostic Statistical Manual Mental Disorders , Fourth Edition criterion dementia Major depressive episode within 6 month screen Treatment entacapone , tolcapone , neuroleptic , antidepressant ( except serotoninspecific reuptake inhibitor imipraminics [ desipramine , imipramine , clomipramine amitriptyline ] ) , monoamine oxidase inhibitor ( except selegiline 10 mg/day oral formulation 1.25 mg/day buccal absorption formulation rasagiline 1 mg/day ) , antiemetic ( except domperidone ) within 3 month screen Treatment apomorphine within previous month screen Dosage change concomitant anti Parkinson medication within 4 week screen Any investigational product within 3 month ( within 5 halflives , whichever long ) screen A psychiatric medical condition might place patient increase risk interfere assessment A clinically relevant electrocardiogram ( ECG ) abnormality A history current evidence heart disease , include limited myocardial infarction , angina , congestive heart failure cardiac arrhythmia Phaeochromocytoma Known hypersensitivity ingredient product use Unstable concomitant disease treat change dos medication History current evidence relevant disease context study , i.e . respect safety patient relate study condition , e.g . may influence absorption metabolism ( e.g . hepatic impairment ) investigational drug Any abnormality liver enzymes 2 time upper limit normal range</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>